Skip to main content

Harrow Health, Inc. (HROW)

NASDAQ: HROW · Delayed Price · USD
9.68 -0.14 (-1.43%)
Sep 22, 2021 4:00 PM EDT - Market closed
Market Cap260.33M
Revenue (ttm)62.57M
Net Income (ttm)7.05M
Shares Out26.89M
EPS (ttm)0.27
PE Ratio35.99
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume67,319
Open9.81
Previous Close9.82
Day's Range9.52 - 9.85
52-Week Range4.65 - 11.24
Beta0.92
AnalystsStrong Buy
Price Target15.13 (+56.3%)
Est. Earnings DateNov 8, 2021

About HROW

Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and Visionology, a membership-based online eye health and medication platform. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the devel...

IndustryPharmaceuticals
Founded1998
Employees125
Stock ExchangeNASDAQ
Ticker SymbolHROW
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for Harrow Health stock is "Strong Buy." The 12-month stock price forecast is 15.13, which is an increase of 56.30% from the latest price.

Price Target
$15.13
(56.30% upside)
Analyst Consensus: Strong Buy

News

Harrow Health Provides $13.5 Million Senior Secured Loan to Melt Pharmaceuticals

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow Health, Inc. (Nasdaq: HROW), an ophthalmic-focused healthcare company, and Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company develop...

2 weeks ago - Business Wire

Harrow Health Acquires Japan-Approved Ophthalmic Injection For Undisclosed Sum

For an undisclosed amount, Harrow Health Inc (NASDAQ: HROW) has agreed to acquire MAQ-100 U.S. and Canadian commercial rights from Wakamoto Pharmaceutical Co Ltd. MAQ-100 is a preservative-free triamcin...

1 month ago - Benzinga

Harrow Health Acquires Ophthalmic Surgical Drug Candidate From Wakamoto Pharmaceutical Co., Ltd.

NASHVILLE, Tenn. & TOKYO--(BUSINESS WIRE)---- $HROW--Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic‑focused healthcare company, today announced that it has entered into an agreement with Wakamoto Pha...

1 month ago - Business Wire

Harrow Health to Participate in Two Upcoming Virtual Investor Conferences

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that Mark L. Baum, Chief Executive Officer, and Andrew Boll, Ch...

1 month ago - Business Wire

Harrow Health (HROW) Reports Q2 Loss, Tops Revenue Estimates

Harrow (HROW) delivered earnings and revenue surprises of 15.38% and 16.02%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Harrow Health: Q2 Earnings Insights

Shares of Harrow Health (NASDAQ:HROW) were flat after the company reported Q2 results. Quarterly Results Earnings per share decreased 1000.00% year over year to ($0.11), which missed the estimate of ($0...

1 month ago - Benzinga

Harrow Health Announces Second Quarter 2021 Financial Results

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced record results for the second quarter and first half ended June...

1 month ago - Business Wire

What's in Store for Harrow Health (HROW) in Q2 Earnings?

Harrow Health (HROW) Q2 results are likely to reflect growth coming from the launch of Visionology, the company's direct-to-consumer eyecare platform.

1 month ago - Zacks Investment Research

Analysts Estimate Harrow Health (HROW) to Report a Decline in Earnings: What to Look Out for

Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Harrow Health (HROW) Gains As Market Dips: What You Should Know

In the latest trading session, Harrow Health (HROW) closed at $8.97, marking a +0.56% move from the previous day.

1 month ago - Zacks Investment Research

Is Harrow Health (HROW) Stock Outpacing Its Medical Peers This Year?

Is (HROW) Outperforming Other Medical Stocks This Year?

1 month ago - Zacks Investment Research

Harrow Health Acquires Patented Ophthalmic Surgical Drug Candidate from Sintetica

NASHVILLE, Tenn. & MENDRISIO, Switzerland--(BUSINESS WIRE)---- $HROW--Harrow Health Acquires Patented Ophthalmic Surgical Drug Candidate from Sintetica

1 month ago - Business Wire

Harrow Health to Announce Second Quarter 2021 Financial Results on August 10, 2021

NASHVILLE, Tenn., July 26, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that it will release its financial results for the secon...

1 month ago - GlobeNewsWire

NovaBay Pharmaceuticals Partners with Harrow Health's ImprimisRx® to Promote Prescription Avenova

EMERYVILLE, Calif. & NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW #Avenova--NovaBay partners with ImprimisRx to promote prescription Avenova.

2 months ago - Business Wire

Down 14% in 4 Weeks, Here's Why You Should You Buy the Dip in Harrow (HROW)

The heavy selling pressure might have exhausted for Harrow (HROW) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in re...

2 months ago - Zacks Investment Research

Bet on 4 Low-Beta MedTech Stocks to Ride the Choppy Market

Stocks like Henry Schein (HSIC), BellRing Brands (BRBR), Harrow Health (HROW) and West Pharmaceuticals Services (WST) are solid low-beta picks with strong fundamentals.

Other symbols:BRBRHSICWST
2 months ago - Zacks Investment Research

Harrow (HROW) Surges 12%: Is This an Indication of Further Gains?

Harrow (HROW) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the...

2 months ago - Zacks Investment Research

Harrow Health Announces Closing of $20 Million Aggregate Principal Amount Offering of 8.625% Senior Notes Due 2026

NASHVILLE, Tenn., June 17, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) (“Harrow Health” or the “Company”), an ophthalmic-focused healthcare company, today announced the closing of its un...

3 months ago - GlobeNewsWire

Harrow Health Announces Pricing of $17.5 Million Aggregate Principal Amount Offering of 8.625% Senior Notes Due 2026

NASHVILLE, Tenn., June 14, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) (“Harrow Health” or the “Company”), an ophthalmic-focused healthcare company, today announced the pricing of its un...

3 months ago - GlobeNewsWire

Harrow Health Announces Offering of $17.5 Million of 8.625% Senior Notes Due 2026 and “BB” Rating from Egan-Jones

NASHVILLE, Tenn., June 14, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) (“Harrow Health” or the “Company”), an ophthalmic-focused healthcare company, today announced that it has commenced...

3 months ago - GlobeNewsWire

Harrow Health: Return On Capital Employed Insights

Harrow Health (NASDAQ:HROW) posted a 7.77% decrease in earnings from Q4. Sales, however, increased by 5.81% over the previous quarter to $15.44 million.

3 months ago - Benzinga

Harrow Health Launches New Corporate and Investor Website

NASHVILLE, Tenn., June 01, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) (“Harrow Health” or the “Company”), an ophthalmic-focused healthcare company, today announced the launch of its new...

3 months ago - GlobeNewsWire

Leading Peer-Reviewed Ophthalmic Journal Publishes Study on ImprimisRx's Proprietary Klarity-C® Drops

Multi-center Retrospective Study Demonstrates Statistically Significant Reduction in Signs and Symptoms of Dry Eye Disease Multi-center Retrospective Study Demonstrates Statistically Significant Reducti...

4 months ago - GlobeNewsWire

Recap: Harrow Health Q1 Earnings

Shares of Harrow Health (NASDAQ:HROW) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 102.00% year over year to $0.01, which beat ...

4 months ago - Benzinga

Harrow Health Announces Record First Quarter 2021 Financial Results

Highlights for First Quarter 2021:

4 months ago - GlobeNewsWire